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Esophageal adenocarcinoma is a cancer with rising incidence and poor survival. Most such 
cancers arise in a specialized intestinal metaplastic epithelium, which is diagnostic of 
Barrett’s esophagus. In a genome-wide association study, we compared esophageal 
adenocarcinoma cases (n=2,390) and patients with precancerous Barrett’s esophagus 
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(n=3,175) with 10,120 controls in two phases. For the combined case group we identified 
three new associations. The first is on 19p13 (rs10419226, P=3.6×10−10) in CRTC1 (CREB-
regulated transcription co-activator), whose aberrant activation has been associated with 
oncogenic activity. A second is on 9q22 (rs11789015, P=1.0×10−9) in BARX1, which 
encodes a transcription factor important in esophageal specification. A third is on 3p14 
(rs2687201, P=5.5×10−9) near the transcription factor, FOXP1, which regulates esophageal 
development. We also refine a previously-reported association with Barrett’s esophagus near 
the putative tumor suppressor gene, FOXF1, on 16q24, and extend our findings to now 
include esophageal adenocarcinoma.
A genetic component to the development of Barrett’s esophagus and esophageal 
adenocarcinoma has long been suspected based on prior studies in unrelated individuals and 
familial disease clusters.1–9 This study leverages the resources of the Barrett’s and 
Esophageal Adenocarcinoma Consortium (BEACON), and combines high-quality largely 
population-based epidemiologic studies of esophageal adenocarcinoma and Barrett’s 
esophagus conducted over two decades.
For the discovery phase, we used 1,516 EA cases, 2,416 Barrett’s esophagus cases and 3,209 
controls, all of European ancestry, after rigorous quality control (QC) procedures (Online 
Methods) were applied to the genotyping data. The cases and 2,187 of the controls were 
collected by investigators in BEACON from cohort and case-control studies conducted in 
Western Europe, Australia, and North America. An additional 1,022 cancer-free controls 
were obtained from a study of melanoma10 and included to increase statistical power. All 
cases were histologically confirmed. The distribution of samples by study is given in 
Supplementary Table 1 and their demographic characteristics in Supplementary Table 2. All 
samples were genotyped on the Illumina HumanOmni1-Quad platform.
We performed association analyses on the 922,031 autosomal and X chromosome SNPs that 
passed QC using an additive logistic regression model implemented in GWASTools11 
including as covariates age, sex and the first four eigenvectors from principal component 
analysis (PCA). To assess variants not present on the Illumina HumanOmni1-Quad, we 
performed imputation for each region of interest (Tables 1 and 2). To identify shared genetic 
susceptibility loci for the two conditions, we treated the esophageal adenocarcinoma and 
Barrett’s esophagus cases as a single phenotype. The results are shown in a Manhattan plot 
in Figure 1. We also compared Barrett’s esophagus and esophageal adenocarcinoma 
separately against the controls (Supplementary Figure 1). QQ plots are shown in 
Supplementary Figure 2. The genomic inflation factor λ for analysis of the combined case 
group was 1.039 (1.084 excluding the first four principal components); no evidence for 
population stratification in our data set is indicated.
We selected 94 associated (p < 10−4) SNPs for replication. Of these, 87 were genotyped in 
874 histologically confirmed esophageal adenocarcinoma cases from the Stomach and 
Oesophageal Cancer Study (SOCS), 759 histologically confirmed Barrett’s esophagus cases 
from the UK Barrett’s Oesophagus Gene Study (UK Gene Study) and 6,911 controls, of 
which 1,711 were from the SEARCH Study and 5,200 from the Welcome Trust Case 
Control Consortium 2 (WTCCC2).12 All SOCS, UK Gene Study and SEARCH samples 
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self-identified as Caucasians and were genotyped on a Fluidigm 96.96 Dynamic Array IFC. 
WTCCC2 subjects were of European ancestry as determined by projection onto the first two 
principal components of a PCA of HapMap individuals and were genotyped on a custom 
version of the Illumina Human1.2M-Duo array. Replication analysis was done using an 
additive logistic regression model with sex as a covariate. METAL software 13 was used for 
meta-analysis of the discovery and replication data sets.
The three loci that reached genome-wide significance (P < 5 × 10−8) in the combined case 
group meta-analysis are given in Table 1 and results for all replicated SNPs are given in 
Supplementary Table 3. The most strongly associated SNP for each of the three loci had 
similar ORs in Barrett’s esophagus and esophageal adenocarcinoma. None of the top 
imputed SNPs showed substantially stronger association than the genotyped SNPs.
The most significant locus was at 19p13 (Figure 2a); rs10419226, PMETA(BE+EA) = 
3.55×10−10, odds ratio (OR) = 1.18, 95% confidence interval (CI) = 1.12 – 1.24. Five 
imputed SNPs in high LD with rs10419226 (r2 > 0.85) were genome-wide significant in the 
combined discovery data set and two were also significant in the Barrett’s esophagus 
discovery set (Supplementary Table 4). A second significant locus was at 9q22.32 (Figure 
2b) for rs11789015 PMETA(BE+EA)= 1.02 × 10−9, OR(CI) = 0.83 (0.79–0.88). The third 
genome-wide significant locus was at 3p13 (rs2687201) near FOXP1 (Figure 2c) with 
PMETA(BE+EA)= 5.47 × 10−9, OR(CI) = 1.18 (1.12 – 1.25)
A previous study of Barrett’s esophagus identified the SNP rs9936833, near the putative 
tumor suppressor gene FOXF1.14 A subset of the BEACON samples from the present study 
(2,398 Barrett’s esophagus cases, 2,167 controls) were used in the replication analysis of 
rs9936833 (P = 5.13 × 10−4, OR(CI) = 1.16 (1.07 – 1.27)). With the additional samples used 
here (18 Barrett’s esophagus cases and 1,042 controls) the p-value was more significant 
(PDISCOVERY(BE) = 1.69 × 10−4), but with no change in the odds ratio (OR(CI) = 1.16 (1.07 
– 1.26)). This SNP was associated with esophageal adenocarcinoma (PDISCOVERY(EA) = 
2.06 × 10−3, OR(CI) = 1.16 (1.05 – 1.27)) (Table 2).
Examining the regional association plot of chromosome 16 near rs9936833 for the combined 
data (Figure 2d) we identified four nearby SNPs that had more significant P-values than 
rs9936833. To test the independence of these associations, this region was fine-mapped 
using conditional analysis to assess whether the associations were due to one or multiple 
variants. The discovery and replication results are shown in Table 2, with conditional 
analysis results in Table 3. Our results indicate that these markers define a set of complex 
susceptibility alleles; with between two and four independent loci.
The previous study of Barrett’s esophagus also identified rs9257809 in the major 
histocompatibility complex (HLA) as being associated with increased risk of Barrett’s 
esophagus.14 The significance in our extended data set (PDISCOVERY(BE) = 0.11, OR(CI) = 
1.11 (0.99 – 1.29)) is not substantially different from the original replication results (P = 
0.083, OR(CI) = 1.13 (0.98 – 1.30)). We found a similar OR for esophageal adenocarcinoma 
as in Barrett’s esophagus, suggesting the previously identified genome-wide significant 
Barrett’s esophagus association also plays a role in esophageal adenocarcinoma risk 
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(PDISCOVERY(EA) = 0.09, OR(CI) = 1.14 (0.97 – 1.32); PDISCOVERY(BE+EA) = 0.06, OR(CI) 
= 1.12 (1.01 – 1.27)).
A previous report using BEACON data showed that Barrett’s esophagus and esophageal 
adenocarcinoma risk is influenced by a large number of common genetic variants, and that a 
large proportion of the genes affecting risk of these two conditions are shared between 
them.15 These findings informed our choice of analysis approach with a primary focus on 
the combined esophageal adenocarcinoma and Barrett’s esophagus samples. The utility of 
this approach was borne out in the results presented here. The ORs after meta-analyses 
comparing esophageal adenocarcinoma cases vs. controls and Barrett’s esophagus cases vs. 
controls for our top five loci are very similar, whereas direct comparison of the two case 
types revealed no significant differences (data not shown). Combining the two case types 
allows these SNPs to clearly achieve genome-wide significance in the combined data sets 
(Table 1).
The SNPs in 19p13.11, rs10419226 and rs10423674, are intronic CRTC1 (CREB-regulated 
transcription co-activator) variants associated with oncogenic activity.16 Phosphorylation of 
CRTC1 is regulated by the tumor suppressor kinase LKB1. Down-regulation or loss of LKB1 
expression in human esophageal cancer cell lines and patient samples resulted in activated 
CRTC1 signaling and the transcriptional activation of downstream targets including LYPD3, 
which is associated with cancer metastasis leading to the promotion of esophageal cancer 
cell migration and invasion.16
rs10419226 has been shown to be an expression quantitative trait loci (eQTL) for PIK3R2 in 
lymphoblastoid cell lines.17 PIK3R2 is known to be involved in cancer18 and is expressed in 
gastrointestinal tumors.19 PIK3R2 is also known to interact with epidermal growth factor 
(EGF), which plays an important physiological role in the maintenance of esophageal and 
gastric tissue integrity. The biological effects of salivary EGF includes healing of oral and 
gastroesophageal ulcers and inhibition of gastric acid secretion.20 Furthermore the EGF 
receptor has been found in gastrointestinal tissue and demonstrates increased expression in 
BE and esophageal adenocarcinoma.21 The G/G genotype for the SNP EGF A61G is 
associated with a two- to four-fold increased risk of esophageal adenocarcinoma.22,23
There are several SNPs in high LD (r2 > 0.9) with rs10419226. Three of these, rs200331191, 
rs139340769 and rs8102046, lie in a region of probable promoter and enhancer activities 
across multiple cell lines.24 The intronic CRTC1 SNP rs10423674 influences age at 
menarche.25 The basis of this pleiotropic effect is unclear, but may be related to obesity as 
CRTC1−/− mice are hyperphagic and obese.26 rs10423674 is an eQTL for PBX4 in 
lymphoblastoid cell lines.
The nearest gene to the peak SNP on chromosome 3 (rs2687201) is FOXP1. The 
transcription factors FOXP1 and FOXP2 cooperatively regulate lung and esophagus 
development and FOXP1 is a therapeutic target in cancer.27,28 The FOX family is 
overexpressed in esophageal cancer.14 There are several SNPs in high LD (r2 > 0.8) with 
rs2687201 which lie within enhancer histone marks. One of them, rs7626449, is at a site 
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where there is also evidence from DNase-seq for transcription factor binding in esophageal 
epithelial cells.29
The SNP rs11789015 lies in an intron of BARX1, a homeobox transcription factor known to 
be involved in esophageal and trachea differentiation in developing mouse embryos and 
associated with down-regulation of Wnt pathway activity in stomach morphogenesis and 
specification.30 The BARX1 promoter region is hypermethylated in gastric cancer (GC) cell 
lines and patient samples, with BARX1 mRNA expression in GC tissues and cell lines 
reduced.31 rs11789015 lies in a region where histone marks denote likely promoter activity. 
rs11789015 also alters a known regulatory motif for the transcription factor FOXP1. A 
correlated SNP, rs62574346 (r2=0.97 with rs11789015), resides where there is also evidence 
from DNase-seq for transcription factor binding in esophageal epithelial cells.29
A subset of the BEACON data presented here (Supplementary Figure 3a) formed part of the 
replication arm of a recent Barrett’s esophagus GWAS.14 A primary finding from that work 
was a Barrett’s esophagus association at 16q24 SNP rs9936833. Here we found clear 
evidence this locus is also associated in esophageal adenocarcinoma (PDISCOVERY(EA) = 
2.06 × 10−3, OR(CI) = 1.16 (1.05 – 1.27), as did a recent small study (316 esophageal 
adenocarcinoma cases, 602 controls; OR(CI) = 1.21 (0.99 – 1.47)).32 Two other SNPs near 
rs9936833, rs2178146 and rs3111601, have stronger and more significant associations in 
esophageal adenocarcinoma cases (Table 2 and Supplementary Figure 3b).
Since the size and direction of effect of the Barrett’s esophagus-associated SNPs at 16q24 
were similar in esophageal adenocarcinoma, we used the combined Barrett’s esophagus and 
cancer data to identify other SNPs which are more significantly associated in 16q24 than 
rs9936833 (Table 2). One of these is rs3111601, which is in high LD (r2 = 0.75) with 
rs9936833. All of the SNPs in high LD with rs3111601 are intergenic, although rs1979654 
(r2=0.64 with rs3111601) stands out as having excellent regulatory potential across a wide 
range of cell types and is likely to affect protein binding, chromatin structure and histone 
modification.29 There was evidence for additional independent signals in the region at 
rs3950627 (38kb nearer to FOXF1) and rs2178146 (64kb nearer to FOXF1), where both had 
similar P-values to rs3111601 (Table 2 and Figure 2d), but were in only modest LD (r2 < 
0.2) with rs3111601. Neither are good regulatory candidates, although rs8045253 
(imputation association PDISCOVERY(BE+EA) = 8.04 × 10−5), in r2=0.63 with rs3950627, 
changes a motif for the transcription factor FOXP1. Changing the way that FOXP1 binds to 
this region is particularly interesting in light of our association findings on chromosome 3.
In summary, we report the first genome-wide association study of esophageal 
adenocarcinoma, and the first to examine this cancer together with its precancerous lesion, 
Barrett’s esophagus. Consistent with our findings showing extensive polygenic overlap 
between esophageal adenocarcinoma and Barrett’s esophagus,15 our most significant results 
were for cancer and pre-cancer combined. Together, these findings suggest that much of the 
genetic basis for esophageal adenocarcinoma lies in the development of Barrett’s esophagus, 
rather than progression from Barrett’s esophagus to esophageal adenocarcinoma. We found 
three novel genome-wide significant loci for esophageal adenocarcinoma and Barrett’s 
esophagus combined, and extended existing findings at the FOXF1 and HLA loci. One of the 
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novel regions is chromosome 3p13, near FOXP1, a gene encoding a transcription factor 
which regulates esophageal development. Interestingly, two of the other regions 
(BARX1/9q22.32 and FOXF1/16q24.1) contain risk associated SNPs which disrupt binding 
of FOXP1. Further dissection of these loci is likely to lead to insights into the etiology of 
this rapidly fatal cancer.
Online Methods
DISCOVERY
Study subjects—Cases of Barrett’s esophagus and esophageal adenocarcinoma, together 
with associated population controls, were collected by investigators in the BEACON 
consortium. A subset of these individuals with European ancestry from epidemiologic 
studies conducted in Western Europe, Australia, and North America over the past twenty 
years were used in the Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility 
Study (BEAGESS) study. To increase the statistical power of the study we included 
additional controls from a hospital based case-control study of melanoma.10 These controls 
(“MD Anderson controls”) were cancer-free friends or acquaintances of European ancestry 
who had accompanied melanoma patients to their clinical visits at the MD Anderson Cancer 
Center in Houston, Texas. The distribution of samples by study is given in Supplementary 
Table 1.
Histological confirmation of esophageal adenocarcinoma was carried out for all esophageal 
adenocarcinoma studies. Similarly, Barrett’s esophagus was histologically confirmed via 
identification of goblet cells in metaplastic columnar epithelium in a biopsy taken from the 
esophagus. Age, sex (Supplementary Table 2) and other esophageal adenocarcinoma/
Barrett’s esophagus risk factors were collected by all of the included studies via 
standardized questionnaires, usually through personal interviews. All recruited participants 
gave informed consent and this project was approved by the ethics boards of each 
participating institution.
Genotyping—BEAGESS specimens were shipped to the Fred Hutchinson Cancer 
Research Center (Seattle, WA) where they were processed and genotyped in three batches. 
In each batch, samples on each genotyping plate were stratified and balanced according to 
case/control status, study, and gender with samples assigned to plates randomly within those 
strata. Genotyping of DNA from buffy coat or whole blood was performed using the 
Illumina HumanOmni1-Quad platform. MD Anderson controls were genotyped using the 
Illumina HumanOmni1-Quad platform at the Johns Hopkins University Center for Inherited 
Disease Research (CIDR). SNP annotations were based on version H of the Illumina product 
files and corresponded to the Genome Reference Consortium GRCh37 release.
Quality control—Quality assurance and quality control (QA/QC) of the BEAGESS and 
MD Anderson data sets were carried out independently by the Genetics Coordinating Center 
at The University of Washington following standard procedures33. QA/QC of the MD 
Anderson data set was described previously10. BEAGESS samples with call rate < 95%, 
admixture of more than one DNA source, or unexpected relatedness (including unexpected 
duplicates) or misannotated sex that could not be explained were removed from the data set. 
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We looked for batch and plate effects using intensity data and allelic frequency and checked 
for case control associations with different experimental factors. No important batch or plate 
effects or case control associations with experimental factors were found. We used 
heterozygosity, sex chromosome intensity data, identity by descent (IBD) analysis and 
visualization of B allele frequency (BAF) and log R ratio (LRR) plots to identify samples 
that had one or more of misannotated sex, unexpected relatedness or were sample 
mixtures.34 Two additional sample mixtures were removed from the data set. After further 
sample filtering to keep only unrelated European ancestry samples (see next section), 2,416 
Barrett’s esophagus cases, 1,516 esophageal adenocarcinoma cases and 2,187 controls 
remained. These samples were combined with 1,022 European ancestry controls from the 
MD Anderson data set for discovery analysis.
SNPs were clustered using Illumina’s GenomeStudio software and defining SNP clusters 
using all samples with a call rate > 95%. SNPs that had either a GenTrain score < 0.6 or a 
cluster separation value < 0.4 had their genotypes set to missing. Additionally, we filtered 
SNPs that were intensity only, had a missing call rate > 5%, had a Hardy Weinberg 
equilibrium p-value over controls >= 10−4, had a discordance among any of the duplicate 
pairs, or had a Mendelian error in either BEAGESS families or HapMap trios. These filters 
were combined with similar filters calculated for the MD Anderson data set.10 Additionally, 
we removed a further 344 SNPs that were discordant in the same HapMap control samples 
(n=3) run in both the BEAGESS and MD Anderson data sets. After QA/QC a total of 
926,923 SNPs remained for analysis.
Principal Components Analysis—We performed Principal Component Analysis (PCA) 
as a two-step process using the SNPRelate software. First, we used PCA to define a 
homogeneous set of European ancestry samples in the BEAGESS data set. We did this by 
running PCA on a set of 6,248 unrelated (except for six two-person families) subjects each 
of which was an EA case, a BE case, or a control. A majority of these subjects (~98%) self-
identified their race as “White” and a scatterplot of all subjects along the axes of the first 
two eigenvectors showed the majority of samples formed a tight cluster (Supplementary 
Figure 4). Therefore, we computed the means and standard deviations (SD) of the first two 
eigenvectors and defined any sample that fell within a two SD rectangle of both eigenvector 
means to be of homogeneous European ancestry (n=6,125).
Second, we ran PCA on the combined data set (n=7,147) consisting of the BEAGESS 
European ancestry samples (n=6,125) and the similarly defined set of MD Anderson 
controls (n=1,022). The intent here was to identify eigenvectors to include as covariates in 
our model to adjust for population differences that were present in the remaining European-
ancestry-only samples.35,36 For this analysis we selected 65,774 SNPs that were non-
monomorphic, autosomal, passed quality control, had missing call rate < 5%, minor allele 
frequency > 5%, did not have an LD value > 0.2 between any two SNPs in a sliding window 
of 500K bases, and were not in the LCT gene (2q21), HLA region or polymorphic regions 
on chromosomes eight (8p23) and seventeen (17q21.31). We included the first four 
eigenvectors as covariates in the association test model to account for population 
stratification by ancestry since they were significantly correlated with case-control status 
and a scree plot showed that the variance accounted for by each eigenvector flattened out 
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after these four eigenvectors (data not shown). To check that only genome-wide variation 
was detected we computed the absolute value of the correlation coefficient of each 
eigenvector against the genotypes for each SNP. We observed one small region of high 
correlation (ρ = ~0.4) between eigenvector one with chromosome two which may indicate 
long-range LD with the LCT gene.
Statistical Analysis—After excluding six related samples and six other samples that had 
missing call rate > 2%, we ran a case-control analysis of the remaining 7,135 samples: 3,928 
cases (1,514 EA and 2,414 BE) vs. 3,207 controls. We used an additive logistic regression 
model with case status regressed on each SNP’s genotype score (coded as 0, 1, or 2 for BB, 
AB and AA) including covariates age, sex and the first four PCA eigenvectors to compute 
the odds ratios (OR) and 95% confidence intervals (95% CI) relating risk of EA or BE to a 
given SNP variant. To test SNPs on the X chromosome, male genotypes were coded as 0 
and 2 and female genotypes as 0, 1 and 2. After filtering SNPs that did not pass quality 
control and SNPs with a minor allele frequency < 1% the λ value was 1.04. The QQ plot is 
shown in Supplementary Figure 2. We also compared Barrett’s esophagus and esophageal 
adenocarcinoma cases separately against the controls using the same model. The 
corresponding Manhattan and QQ plots are shown in Supplementary Figures 1 and 2, 
respectively. Analysis was carried out in the R statistical programming language37 using the 
Bioconductor packages GWASTools11 and SNPRelate.38
Using the combined BE + EA discovery data set we performed a step-wise series of nested 
logistic regression analyses to test the independence of the associations in 16q24 near 
rs9936833. We used the same logistic regression model and covariates as in our primary 
analysis, and also fitted rs3950627 as a covariate since it was the most significant SNP 
100kb up or downstream of rs9936833. This conditional analysis identified rs2178146 as the 
most significant SNP 100kb up or downstream of rs9936833. We repeated this analysis four 
more times identifying and adding to each successive model rs2178146, rs3111601, 
rs1490865, and rs13332095, respectively, stopping when the p-value of the most significant 
remaining SNP had P > 0.01 (Table 3).
Imputation—To assess the impact of variants not present on the Illumina HumanOmni1-
Quad, we imputed genotypes using the MaCH39 software and a European reference panel 
from the 1000 Genomes project. At each region in Tables 1 and 2 imputation was done in 
two steps. First, haplotypes were estimated in a pre-phasing step. Second, missing alleles for 
additional SNPs were imputed onto these phased haplotypes using Minimac39 and a publicly 
available reference panel of haplotypes from European ancestry populations. SNPs with 
very different allele frequencies (a Chi Square statistic > 40 in a test for difference in allele 
frequency) between the BEACON data and the reference panel were removed prior to the 
second step. SNPs with MACH imputation r2 < 0.3 (a measure of imputation quality) and 
SNPs with a minor allele frequency < 1% were also removed. Association analysis between 
imputed SNPs and disease status was performed using the same regression model as for 
genotyped SNPs, but with dosage probabilities as predictors, rather than the actual genotype 
calls. All association tests were two-sided. Linkage disequilibrium (LD) calculations (r2) 
were computed with the discovery data when the two SNPs being compared were both 
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genotyped, otherwise the European ancestry samples from Phase 1 of the 1000 genomes 
project were used.
REPLICATION
SNP selection—We selected post-QA/QC SNPs for replication that had a p-value from 
discovery < 10−4 and a minor allele frequency > 1%. This yielded 406 SNPs: 179 from 
Barrett’s esophagus and esophageal adenocarcinoma vs. controls, 105 from esophageal 
adenocarcinoma vs. controls and 122 from Barrett’s esophagus vs. controls, of which 321 
were unique. A subset of these SNPs (n=111) were selected via LD pruning with PLINK 
using the command clump40; if a SNP was in LD > 0.5 with any other SNP(s) in the list, the 
SNP with lowest p-value was selected for replication. For each of the ten SNPs on this list 
with the smallest p-value, we selected an extra “proxy” SNP to include in case the top SNP 
was not successfully genotyped in the replication set. These proxy SNPs were ones in high 
LD with the top SNP, but with a less significant p-value. We visually examined cluster plots 
of all SNPs and kept only those that were high quality. SNPs were rank ordered by p-value 
and replication attempted for the top 94.
Study Subjects—The replication cohort consisted of Barrett’s esophagus cases, 
esophageal adenocarcinoma cases and two control sets. Barrett’s esophagus cases were 
identified at endoscopy with a confirmed histopathological diagnosis of intestinal metaplasia 
from the UK Barrett’s Oesophagus Gene Study. esophageal adenocarcinoma cases were 
selected from the Stomach Oesophageal Cancer Study and had an ICD coding of malignant 
neoplasm of the esophagus (C15) and a pathological diagnosis of adenocarcinoma. One set 
of controls came from the SEARCH study which ascertains eligible cases of breast, ovary, 
prostate, colorectal, melanoma and endometrial cancer from the UK Eastern Cancer 
Registration and Information Centre. Controls were ascertained by frequency matching on 
age (five-year age bands) and sex to the esophageal adenocarcinoma and Barrett’s 
esophagus cases excluding individuals with a past history of cancer (excluding non-
melanoma skin cancer). All recruited participants gave informed consent and the studies 
have been approved by the relevant institutional ethics review board. The other set of 
controls was from the Wellcome Trust Case Control Consortium 2 (WTCCC2).
Genotyping—Barrett’s esophagus cases, esophageal adenocarcinoma cases and SEARCH 
controls were genotyped using the FluidigmTM high-throughput platform and Fluidigm 
96.96 Dynamic ArraysTM according to the manufacturer’s instructions and read using the 
Fluidigm EP1TM. Each array is capable of running 96 samples against 96 SNP assays. 
Cases and controls were plated out in sets of 96 samples and combined into 384-well arrays 
for genotyping with the cases and controls mixed on each 384-well plate. Genotypes were 
automatically called using the BioMark Genotyping AnalysisTM software, but all cluster 
plots were also checked manually and adjusted as necessary. The WTCCC2 controls were 
genotyped on a custom version of the Illumina Human1.2M-Duo array.
Quality Control—We filtered Barrett’s esophagus cases, esophageal adenocarcinoma 
cases and SEARCH controls with low call rate, inconsistent gender, were duplicates or had 
self-reported ethnicity of “non-white” or “missing”. This left 759 Barrett’s esophagus cases, 
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874 esophageal adenocarcinoma cases and 1711 SEARCH controls. We excluded SNPs 
with missing call rate ≥ 5%, with significant differential missing call rates in cases and 
controls (p < 5×10−4), with low minor allele frequency (defined as <1%), and with 
significant departure from Hardy-Weinberg equilibrium (p<0.0005), leaving 87 post-QC 
SNPs. We applied standard sample and SNP exclusion criteria to the WTCCC2 controls 
keeping 5,190 post-QC European ancestry samples. There were 67 post-QC SNPs in the 
WTCCC2 controls in common with the 87-post QC SNPs from the BE cases, EA cases and 
SEARCH controls.
Statistical analysis—Each of the 87 SNPs was run using an additive logistic regression 
model with case status regressed on the SNPs genotype and including sex as a covariate. 
The analysis focus was on the comparison of BE and EA cases against controls, but we also 
ran each case type separately against the controls. The final data set used for replication 
consisted of 759 BE cases and 874 EA cases. For 67 SNPs the control set consisted of 6,911 
samples; 1711 SEARCH controls and 5200 WTCCC2 controls. For 20 SNPs that were not 
genotyped in the WTCCC2 data only the 1,711 SEARCH controls were used. The R 
statistical programming language was used for all analyses.
META-ANALYSIS
We used the inverse variance-based method in the METAL software13 to perform a meta-
analysis of the discovery and replication data sets. This approach weights the effect size 
estimates (β-coefficients from the discovery and replication regression models) by their 
standard error estimates and calculates an overall Z-score and p-value. This was done 
separately for each sample set.
BIOINFORMATICS/FUNCTIONAL GENOMICS
Each region of interest was interrogated using the tools eQTL browser, HaploReg, 
RegulomeDB, and the UCSC Genome Browser.
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Figure 1. 
Plot of genome-wide association results from the discovery data for the combined Barrett’s 
esophagus and esophageal adenocarcinoma cases using an additive logistic regression model 
with age, sex and the first four eigenvectors from principal components analysis as 
covariates. Results are shown for 3,928 cases (2414 Barrett’s esophagus, 1514 esophageal 
adenocarcinoma) and 3,207 controls for 801,552 autosomal and X chromosome SNPs that 
passed quality control and have a minor allele frequency > 1%. Chromosomes are delineated 
by alternating colors, as labeled on the x-axis. The y-axis shows the −log10 P-values.
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Figure 2. 
Regional association plots showing genotyped and imputed SNPs from the discovery data 
for the combined Barrett’s esophagus + esophageal adenocarcinoma cases for three newly 
discovered loci (a–c) and one previously identified locus (d). Genotyped SNPs are indicated 
by solid triangles, and imputed SNPs are indicated by hollow circles. The top-ranked SNP at 
each locus is shown as a solid purple diamond, except in (d) where it is rs9936833. SNPs are 
ordered by genomic location. The color scheme indicates linkage disequilibrium between 
the top ranked SNP and other SNPs in the region using the r2 value calculated from the 1000 
genomes project. The y-axis is the −log10 p-value computed from 3,928 cases (2414 
Barrett’s esophagus, 1514 esophageal adenocarcinoma) and 3,207 controls. Imputation P 
values for all SNPs are plotted. Note that imputed and genotyped P-values for genotyped 
SNPs differ slightly because for the imputed result, the analysis was based on dosage scores, 
whereas with genotyped SNPs, the hard genotype calls are used. The recombination rate 
from CEU HapMap data (right side y axis) is shown in light blue. (a) Chromosome 19p13 
region. (b) Chromosome 9q22 region. (c) Chromosome 3p13 region. (d) Chromosome 
16q24 region.
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Figure 3. 
Levine et al. Page 17
Nat Genet. Author manuscript; available in PMC 2014 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
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Figure 5. 
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